<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-TAM25501-3SL-92-WSN"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S1407 IS: Anyone But China Safe Drug Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-04-10</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 1407</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250410">April 10, 2025</action-date><action-desc><sponsor name-id="S374">Mr. Cotton</sponsor> introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSFI00">Committee on Finance</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To ban the use of Federal funds for the purchase of drugs manufactured in the People's Republic of China, and for other purposes.</official-title></form><legis-body display-enacting-clause="yes-display-enacting-clause"><section section-type="section-one" id="S1"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Anyone But China Safe Drug Act</short-title></quote> or the <quote><short-title>ABC Safe Drug Act</short-title></quote>.</text></section><section id="idA26396DAACF74693B512822284A04A41"><enum>2.</enum><header>Federal health program purchase of drugs</header><subsection id="id6674CA266D444FCEA3B0013A5E80DF51"><enum>(a)</enum><header>Federal health program purchase of drugs</header><paragraph id="idB74AB7452ED948BD85ED2F8DB994F8C7"><enum>(1)</enum><header>In general</header><text>Notwithstanding any other provision of law, with respect to the purchase of a drug by the Department of Health and Human Services, the Department of Veterans Affairs, the Department of Defense, or any other Federal health care program (as defined in section 1128B(f) of the Social Security Act (42 U.S.C. 1320a–7b(b))), the following shall apply:</text><subparagraph id="id77148d1d56cd43d487ee291983d6f99d"><enum>(A)</enum><text>Beginning on January 1, 2028, such agency or program may purchase only drugs for which 60 percent or more of the active pharmaceutical ingredients are manufactured in countries described in paragraph (2).</text></subparagraph><subparagraph id="id5A3EE6188A4247D3BAFF7A15E32FD6B9"><enum>(B)</enum><text>Beginning on January 1, 2030, such agency or program may purchase only drugs for which 100 percent of the active pharmaceutical ingredients are manufactured in countries described in paragraph (2).</text></subparagraph></paragraph><paragraph id="id676F9D4F98234168A014F63A8A54273B"><enum>(2)</enum><header>Countries described</header><text>The countries described in this paragraph are countries—</text><subparagraph id="id01D1F074DB4A48F389845EA31E5AA28E"><enum>(A)</enum><text>other than People’s Republic of China; and </text></subparagraph><subparagraph id="id820600DC641240B0956053CEB4E5D26A"><enum>(B)</enum><text>that meet the health and safety standards of the Food and Drug Administration. </text></subparagraph></paragraph><paragraph id="id0064ECF0F20346338BB1803013F3699E"><enum>(3)</enum><header>Waivers</header><text>The Secretary of Health and Human Services may issue waivers of the requirements under paragraph (1) for any agency or program that is unable to meet such requirements and demonstrates a need for the waiver. No waiver may be issued under this paragraph for drugs that are purchased on or after January 1, 2031.</text></paragraph></subsection><subsection id="idA9B9E27A1314404295944382CA6D2856"><enum>(b)</enum><header>Labeling requirement</header><text>Section 502 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/352">21 U.S.C. 352</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="idCE57E31B5B3840D2B2B09ECB35EB8855"><subsection id="id0FB013527CDF4A10873ABD300B21BD90"><enum>(hh)</enum><text>If it is a drug and its labeling does not specify the country of origin of each active ingredient contained in the drug.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section><section id="id96c626f251d54da3bd94739257b0e35a"><enum>3.</enum><header>Temporary 100 percent expensing for pharmaceutical and medical device manufacturing property</header><subsection id="id9b2ff5eb5b094ddabe7a26ef5b61749c"><enum>(a)</enum><header>In General</header><text>For purposes of <external-xref legal-doc="usc" parsable-cite="usc/26/168">section 168(k)</external-xref> of the Internal Revenue Code of 1986, in the case of any qualified pharmaceutical and medical device manufacturing property which is placed in service after December 31, 2024, and before January 1, 2031—</text><paragraph id="id3bfbb41aa75f4e10a76ab7df7b5fce39"><enum>(1)</enum><text>such property shall be treated as a qualified property (within the meaning of such section);</text></paragraph><paragraph id="idc63790dbed284fa68bfb7de8832cdb97"><enum>(2)</enum><text>the applicable percentage otherwise determined under section 168(k)(6) of such Code with respect to such property shall be 100 percent; and</text></paragraph><paragraph id="id2830075c7bc24e04aef6e82cbe41e0b0"><enum>(3)</enum><text>paragraph (8) of such section shall not apply.</text></paragraph></subsection><subsection id="idde0b8912c9e24a20af632351ec1a0535"><enum>(b)</enum><header>Qualified pharmaceutical and medical device manufacturing property</header><text>For purposes of this section, the term <term>qualified pharmaceutical and medical device manufacturing property</term> means any tangible property placed in service in the United States as part of the construction or expansion of property for the manufacture of drugs (as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321(g)</external-xref>) or devices (as defined in section 201(h) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321(h)</external-xref>))).</text></subsection><subsection id="id849e07f304694d6d83bea5879ed0c9f4"><enum>(c)</enum><header>Termination</header><text>This section shall not apply to any property placed in service after December 31, 2030.</text></subsection></section></legis-body></bill> 

